about
New GOLD classification: longitudinal data on group assignment.Clinical application of the COPD assessment test: longitudinal data from the COPD History Assessment in Spain (CHAIN) cohort.Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.Genotype-phenotype relationship in 12 patients carrying cystic fibrosis mutation R334WCompliance with guidelines-recommended processes in pneumonia: impact of health status and initial signs.Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired PneumoniaDistribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN CohortEvaluating respiratory patient disability.Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease.Endobronchial instillations of amphotericin B: complementary treatment for pulmonary mucormycosis.Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome.Prognostic assessment in COPD without lung function: the B-AE-D indices.Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia.Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD.Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study.Erratum: New GOLD classification: longitudinal data on group assignmentInitial management of pneumonia and sepsis: factors associated with improved outcome.Radicular involvement and medullary invasion from a malignant mesothelioma.Multicomponent indices to predict survival in COPD: the COCOMICS study.Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification.Ventricular fibrillation after intrapleural urokinase.[Pneumococcal vaccine recommendations in chronic respiratory diseases].Foreign-body pulmonary embolism.Cyclooxygenase-2 polymorphisms confer susceptibility to sarcoidosis but are not related to prognosis.Prevalence, Knowledge and Attitudes Towards Smoking Among SEPAR Members.A simple algorithm for the identification of clinical COPD phenotypes.Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort.Changes and clinical consequences of smoking cessation in COPD patients: a prospective analysis from the CHAIN cohort.Mitral valve prolapse and sudden deafness.Tobacco smoking increases the risk for death from pneumococcal pneumonia.What has Changed in Community-Acquired Pneumonia in Recent Years?Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.Using PICO Methodology to Answer Questions About Smoking in COPD Patients.World Lung Day.Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease.Empyema of the Thorax in AdultsAge-related risk factors for bacterial aetiology in community-acquired pneumonia
P50
Q30732307-F8E1B3E0-8859-4A65-A35C-B5BB54362774Q30756078-445C9899-5100-4CAF-8232-696BB0F750BCQ30955660-4E45FA1D-C288-4E8E-BECA-7C89A1925A53Q33678356-369BD3F7-1EF0-43C8-9FA6-6D17D016279CQ34281998-C69958D7-F372-4CFC-953A-10B7A7E3858DQ34561776-FED14815-D71D-482A-9AD7-1813E81C77CAQ35108231-BAE7F590-00CE-438A-8CE9-34BBE0F28804Q35883963-33DAB108-9DB7-48EC-8133-C0D293588AD1Q36147971-EB58AF28-8E96-40C5-A38F-9C145D23323FQ37985005-3F7EC7B9-1EBE-486D-ADCD-B80F57375F60Q39299342-B1326D8C-F0A4-44B6-B95D-B2E222CC37EBQ40385845-896A70B4-6582-4174-B25F-BC71D5539533Q40582369-AB8AFA4F-E589-4D04-B936-62592101947DQ40786706-0FBE5375-5C6B-454A-9B6D-4B212F1ADB0DQ41044146-BCE57EF1-9E4B-460A-B504-49BAA4DB98D1Q41542974-FA17BB4A-A4D5-4735-AE24-292A15F29157Q42244046-68960B47-44D6-45EC-98F3-5E032503558CQ42571923-508C3B1D-261C-43A5-B34C-6DA5D91EE3FAQ43592653-CD738259-8C60-4500-905C-F738D273851AQ43792752-6D22F1B1-CE35-4FB8-83AC-DEC5B9E08F9DQ44171299-58ED1DC1-F38B-4A4C-A697-A88BB434C126Q44240409-1BF32E49-E095-41BC-9F26-A36A4F0F6C40Q44465797-D9D88322-53EB-45BD-90B6-5A378343E0EDQ44638397-102E2A68-B53C-48B8-B10A-E0FACE386D54Q45344352-4063E64A-BAB2-4BFF-81FB-FEA3E7BD6C90Q46818427-BAA1FAB3-04F6-4241-89A9-1B0CDD0BBB12Q47579992-9BEF82A3-BE1C-49C4-99D5-F7AA7B1BB965Q47621654-FD475A3F-C8A2-44D6-AE15-90E292472FD3Q48251200-A4AD6879-3FFA-4B07-8559-9B1427DAC9ADQ48958091-BEE81DBB-8221-4CFF-A508-65A6EFE6D3ECQ50145601-0BAA4442-C6EB-4D36-9734-1132030A9CF6Q50458635-A404BED6-39C1-4048-A029-F1AB63E5F547Q51724873-C66C6052-4041-4000-8A6D-62F1204157FAQ51811502-A3401AEA-2896-42EA-BFB0-5C16E57128FDQ51842411-3872B0CE-0160-4369-83C3-24BE57F89503Q53600344-368958EA-9F34-4CBE-AF92-C10E08C74495Q54564972-0043DE69-C695-40F3-B527-DC689990CFCCQ55383429-2DA34CEC-31E7-4587-9A67-81E43F80E086Q56428756-2C1F0E14-1A20-4AD5-B6A2-A5D85EEC3CADQ57237653-46EF5F6E-76E5-433E-8791-BFD1F6F64653
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Inmaculada Alfageme
@en
Inmaculada Alfageme
@nl
Inmaculada Alfageme
@sl
inmaculada alfageme
@es
type
label
Inmaculada Alfageme
@en
Inmaculada Alfageme
@nl
Inmaculada Alfageme
@sl
inmaculada alfageme
@es
altLabel
Inmaculada Alfageme Michavila
@en
Inmaculada Alfajeme Michavila
@en
Inmaculada Alfajeme
@en
prefLabel
Inmaculada Alfageme
@en
Inmaculada Alfageme
@nl
Inmaculada Alfageme
@sl
inmaculada alfageme
@es
P1053
K-2092-2014
P106
P1153
6602891624
6602924150
P21
P31
P3829
P3835
inmaculada-alfageme
P496
0000-0002-5106-1669